Medicare does not cover Ocrevus under Part D, but it may be covered under Part A or B when deemed medically necessary. Beneficiaries must navigate specific settings and potential out-of-pocket costs associated with this treatment.
Understanding Medicare’s coverage of Ocrevus is crucial for beneficiaries managing multiple sclerosis, as the rules can be more complex than many anticipate. While Ocrevus is not covered under Medicare Part D, there are pathways for coverage under Part A and B that hinge on medical necessity and the setting of administration, making it essential for patients to be informed and proactive in navigating their options.
Key Takeaways
- Ocrevus is not covered by Medicare Part D but may be covered under Part A or B in specific settings.
- Beneficiaries could face significant out-of-pocket costs, including a potential 20% coinsurance under Part B.
- Eligibility for coverage requires Ocrevus to be administered by a physician or skilled nursing professional.
- Recent updates for 2026 include a $2,100 out-of-pocket cap for Part D drugs, but Ocrevus is billed under Part B.
- Ocrevus is not eligible for Medicare price negotiation until 2031.
Understanding Medicare Coverage for Ocrevus
Medicare Part D Exclusions and Alternatives
Currently, Ocrevus is not included in Medicare Part D prescription drug coverage. However, some beneficiaries may find that they can receive coverage for Ocrevus if it is determined to be medically necessary by their healthcare provider, particularly when administered by a physician or skilled nursing professional.
Settings That Enable Coverage
The setting in which Ocrevus is administered plays a critical role in determining coverage. For instance, if Ocrevus is given in a certified skilled nursing facility, it may qualify for coverage under Medicare Part A. Alternatively, when administered in an outpatient clinical setting, it may be covered under Medicare Part B, especially if the infusion occurs incident to a hospital stay following an emergency.
Specifics of Part B Coverage
As an infusion disease-modifying therapy for multiple sclerosis, Ocrevus is covered under Medicare Part B when provided in approved outpatient or infusion-center settings. Notably, MVP Health Care’s 2026 policy indicates that specific codes for Ocrevus do not require prior authorization, simplifying access for beneficiaries.
Financial Implications of Ocrevus Coverage
Cost Responsibilities for Beneficiaries
The financial responsibilities for beneficiaries can vary significantly based on which Medicare part provides coverage and any applicable deductibles. When covered under Part A or B, beneficiaries may be liable for standard Medicare cost-sharing, which includes deductibles and coinsurance associated with inpatient or outpatient services.
Out-of-Pocket Cost Considerations
Without supplemental coverage, beneficiaries could face approximately $13,000 annually in Part B coinsurance for Ocrevus, given its list cost of about $65,000. It’s important to note that while out-of-pocket costs for Part D drugs are capped at $2,100 in 2026, Ocrevus is billed under Part B, which does not fall under this cap.
Exceptions to Standard Coverage Rules
Understanding Coverage Exceptions
There are exceptions to the standard non-coverage of Ocrevus, particularly when it is provided as part of a covered facility service. Coverage may also hinge on the drug being deemed medically necessary by a physician, which is a critical factor for beneficiaries to consider.
Incident-to Hospital Stay Coverage
One notable exception pathway for Ocrevus coverage is when it is administered incident to a hospital stay following an emergency. This can provide beneficiaries with additional options for receiving necessary treatment.
Eligibility Criteria for Ocrevus Coverage
Determining Medical Necessity
Eligibility for Ocrevus coverage under Medicare is contingent upon a physician determining that the treatment is medically necessary. This requirement underscores the importance of having thorough discussions with healthcare providers about treatment options.
Setting-Specific Eligibility
Eligibility for coverage under Part A applies when Ocrevus is administered in a certified skilled nursing facility, while Part B coverage is applicable in outpatient clinical settings. Additionally, coverage incident to a hospital stay is limited to situations that occur after an emergency.
Diagnosis Requirements for Coverage
Coverage for Ocrevus and Ocrevus Zunovo is specifically provided for individuals diagnosed with relapsing forms of multiple sclerosis or primary progressive MS. This diagnosis requirement is essential for beneficiaries to understand when seeking coverage.
Recent Updates Impacting Ocrevus Coverage
Current Status of Medicare Coverage
As of now, Medicare Part D does not cover Ocrevus as a prescription drug. However, Medicare plans for 2026 are set to introduce lower prices on select drugs and a $2,100 out-of-pocket cap for Part D, although these changes do not directly affect Ocrevus, which is billed under Part B.
Future Considerations for Ocrevus
Looking ahead, Ocrevus will not be eligible for Medicare price negotiation until 2031, which may impact its affordability for beneficiaries. Additionally, recent clinical data indicates that Ocrevus treatment can slow disability progression in advanced primary progressive MS, highlighting its importance in treatment plans.
Practical Tips for Medicare Beneficiaries
Navigating Coverage Options
Beneficiaries are encouraged to consult with their physician to determine if Ocrevus is medically necessary, as this is a prerequisite for potential coverage. Furthermore, verifying the setting of the Ocrevus infusion is crucial, as coverage can depend significantly on where the drug is administered.
Maximizing Coverage Benefits
To maximize coverage benefits, Medicare recipients should inquire whether their Ocrevus treatment can be billed under Part A or B, given that Part D does not cover the drug. It is also advisable for patients to confirm with the treating facility that they can bill Medicare for Ocrevus services, and consider obtaining Medigap coverage or enrolling in a Medicare Advantage plan to reduce out-of-pocket costs.
Key Takeaways for Medicare Recipients Considering Ocrevus
Navigating Medicare coverage for Ocrevus requires understanding that while it is not covered under Part D, there are specific pathways under Part A and B that may provide access. Beneficiaries should remain aware of potential out-of-pocket costs and the importance of consulting with healthcare providers to effectively navigate their coverage options.